New drug combo aims to fight tough bile duct cancer

NCT ID NCT06938321

Recruiting now Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental drugs, AK130 and AK112, in people with advanced biliary tract cancer (a type of bile duct cancer). The first part finds a safe dose; the second part checks if the combination shrinks tumors. About 135 participants will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK130 and AK112 (two experimental drugs that help the immune system fight cancer)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced biliary tract cancer who have run out of standard therapies.
What could go wrong: This is an early-phase trial with only 135 participants, so results may not apply to everyone. The drugs could cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER

Contacts and locations

Locations

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.